RT Journal Article
SR Electronic
T1 Performance evaluation of the BD SARS-CoV-2 reagents for the BD MAX™ system
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.12.21257120
DO 10.1101/2021.05.12.21257120
A1 Yanson, Karen
A1 Laviers, William
A1 Neely, Lori
A1 Lockamy, Elizabeth
A1 Castillo-Hernandez, Luis Carlos
A1 Oldfied, Christopher
A1 Ackerman, Ronald
A1 Ackerman, Jamie
A1 Ortiz, Daniel A
A1 Pacheco, Sixto
A1 Simner, Patricia J
A1 Young, Stephen
A1 McElvania, Erin
A1 Cooper, Charles K
YR 2021
UL http://medrxiv.org/content/early/2021/05/18/2021.05.12.21257120.abstract
AB Background The RT-qPCR assay for detecting SARS-CoV-2 virus is the favorable approach to test suspected COVID-19 cases. However, discordant results can occur when two or more assays are compared. Variability in analytical sensitivities between assays, among other factors, may account for these differences in reporting.Methods The limits of detection (LOD) for the BD SARS-CoV-2 Reagents for BD MAX™ System (“MAX SARS-CoV-2 assay”), the Biomerieux BioFire® Respiratory Panel 2.1 (“BioFire SARS-CoV-2 assay”), the Roche cobas SARS-CoV-2 assay (“cobas SARS-CoV-2 assay”), and the Hologic Aptima® SARS-CoV-2 assay Panther® (“Aptima SARS-CoV-2 assay”) RT-qPCR systems were determined using a total of 84 contrived nasopharyngeal specimens with seven target levels for each comparator. The positive and negative percent agreement (PPA and NPA, respectively) for the MAX SARS-CoV-2 assay were compared to the Aptima SARS-CoV-2 assay in a post-market clinical study utilizing 708 paired nasopharyngeal specimens collected from suspected COVID-19 cases. Discordant results were further tested by the cobas and BioFire SARS-CoV-2 assays.Results The measured LOD for the MAX SARS-CoV-2 assay (251 copies/mL) was comparable to the cobas SARS-CoV-2 assay (298 copies/mL) and the BioFire SARS-CoV-2 assay (302 copies/mL); the Aptima SARS-CoV-2 assay had a LOD of 612 copies/mL. The MAX SARS-CoV-2 assay had a PPA of 100% (95%CI: [97.3%-100.0%]) and a NPA of 96.7% (95%CI: [94.9%-97.9%]) when compared to the Aptima SARS-CoV-2 assay.Conclusions The MAX SARS-CoV-2 assay exhibited a high analytical sensitivity and specificity for SARS-CoV-2 detection. The clinical performance of the MAX SARS-CoV-2 assay agreed with another sensitive EUA cleared assay.Competing Interest StatementKY, WL, LN, EL, and CKC are employees of Becton, Dickinson and Company. All authors declare no conflicts of interest.Clinical TrialRegistration of this study at ClinicalTrials.gov was not obtained as it did not fulfill the applicable minimum medical device clinical trial requirement criteria as per the Food and Drug Administration Amendments Act. Specifically, this study did not assess health outcomes associated with the use of this assay.Funding StatementThis study was funded by Becton, Dickinson and Company, BD Life Sciences - Integrated Diagnostic Solutions. Non-BD employee authors received research funds to support their work for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Advarra Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request.